BH 3620
Alternative Names: BH-3620Latest Information Update: 04 Apr 2022
At a glance
- Originator Phanes Therapeutics
- Developer Hanmi Pharmaceutical; Phanes Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 04 Apr 2022 Discontinued - Preclinical for Solid tumours in South Korea (Parenteral) (Hanmi Pharmaceutical pipeline, April 2022)
- 15 Dec 2021 Phanes Therapeutics plans to file IND application in 2022
- 20 Jan 2021 Preclinical trials in Solid tumours in South Korea (Parenteral), prior to January 2021 (Hanmi Pharmaceutical pipeline, January 2021)